Versaterm and SiFly Partner to Transform Emergency Response with Next-Generation, Long-Endurance Drones
The partnership combines an advanced drone operations platform with 3-hour flight time…
Warmth in Action: Web3 & FinTech Industry’s Dual-Pronged Response to Hong Kong’s Tai Po Fire
HONG KONG, Dec. 4, 2025 /PRNewswire/ -- Following the fire at Tai…
4D Paths Physics-Inspired QPOR Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial
NEWTON, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- 4D Path, a company…
Burn Blend Releases Comprehensive Gelatin Trick Recipe Based Protocol Guide in Response to Rising Public Interest in Weight-Management Methods
New York City, NY, Nov. 23, 2025 (GLOBE NEWSWIRE) -- The organization…
ECW Announces US$3.5 Million First Emergency Response Grant in Bangladesh
Delivered by UNICEF with a broad consortium of local partners, the new…
BlueWillow Biologics Intranasal Bird Flu Vaccine Shows Signs of Broad Immune Response in Phase I Clinical Trial Published in Nature Communications
ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- BlueWillow Biologics, Inc.,…
ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium
Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM),…
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025
Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus…
Saksoft to Showcase ‘SakCare’ – AI-Powered Critical Service Response Solution for BFS at Dreamforce 2025
BENGALURU, India, Oct. 9, 2025 /PRNewswire/ -- Saksoft, a leader in digital…
BYD improves Assisted Driving system in response to Euro NCAPs ATTO 3 grading
LEUVEN, BELGIUM – BYD has responded to the ’Not Recommended’ grading which…
